Our Papers


Li S, Counter CM. An ultra-sensitive method to detect mutations in human RAS templates. Small GTPases. 2022 Jan;13(1):287-295. doi: 10.1080/21541248.2022.2083895. PMID: 35658790.

Allen SR, Stewart RK, Rogers M, Ruiz IJ, Cohen E, Laederach A, Counter CM, Sawyer JK, Fox DT. Distinct responses to rare codons in select Drosophila tissues. Elife. 2022 May 6;11:e76893. doi: 10.7554/eLife.76893. PMID: 35522036; PMCID: PMC9116940.

Li S, Counter CM. Non-canonical genomic driver mutations of urethane carcinogenesis. PLoS One. 2022 Apr 28;17(4):e0267147. doi: 10.1371/journal.pone.0267147. PMID: 35482806; PMCID: PMC9049545.

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. PMID: 34852220; PMCID: PMC8665414.

Adhikari, H., Kattan, W. E., Kumar, S., Zhou, P., Hancock, J. F., and Christopher M. Counter. “Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.” Nature communications 12, no. 1 (September 2021): 5248. https://doi.org/10.1038/s41467-021-25523-5

Li, S., and Christopher M. Counter. “Signaling levels mold the RAS mutation tropism of urethane.” eLife 10, (May 2021): e67172. https://doi.org/10.7554/eLife.67172

Adhikari, H., and Christopher M. Counter. “Using BioID to Characterize the RAS Interactome.” Methods in molecular biology (Clifton, N.J.)2262 (2021):271–280. https://doi.org/10.1007/978-1-0716-1190-6_16

Peterson, J., Li, S., Kaltenbrun, E., Ozgun, E. and Christopher M. Counter. “Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway.” Sci Rep 1022166 (December 2020). https://doi.org/10.1038/s41598-020-78453-5

Li, S., MacAlpine, D.M., and Christopher M. Counter. “Capturing the primordial Kras mutation initiating urethane carcinogenesis.” Nat Commun 111800 (April 2020). https://doi.org/10.1038/s41467-020-15660-8

Li, Siqi, Allan Balmain, and Christopher M. Counter. “A model for RAS mutation patterns in cancers: finding the sweet spot.Nat Rev Cancer 18, no. 12 (December 2018): 767–77. https://doi.org/10.1038/s41568-018-0076-6.

Fu, Jingjing, Yunkun Dang, Christopher Counter, and Yi Liu. “Codon usage regulates human KRAS expression at both transcriptional and translational levels.J Biol Chem 293, no. 46 (November 16, 2018): 17929–40. https://doi.org/10.1074/jbc.RA118.004908.

Adhikari, Hema, and Christopher M. Counter. “Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability.Nat Commun 9, no. 1 (September 7, 2018): 3646. https://doi.org/10.1038/s41467-018-05692-6.

Xu, MengMeng, Michael Casio, Danielle E. Range, Julie A. Sosa, and Christopher M. Counter. “Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.Clin Cancer Res 24, no. 17 (September 1, 2018): 4271–81. https://doi.org/10.1158/1078-0432.CCR-17-3705.

Kabiri, Zahra, Gediminas Greicius, Hamed Zaribafzadeh, Amanda Hemmerich, Christopher M. Counter, and David M. Virshup. “Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells.J Clin Invest 128, no. 9 (August 31, 2018): 3806–12. https://doi.org/10.1172/JCI99325.

Sasine, Joshua P., Heather A. Himburg, Christina M. Termini, Martina Roos, Evelyn Tran, Liman Zhao, Jenny Kan, et al. “Wild-type Kras expands and exhausts hematopoietic stem cells.Jci Insight 3, no. 11 (June 7, 2018). https://doi.org/10.1172/jci.insight.98197.

Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.Cancer Res 77, no. 22 (November 15, 2017): 6240–52. https://doi.org/10.1158/0008-5472.CAN-16-1190.

Anderson, Grace R., Peter S. Winter, Kevin H. Lin, Daniel P. Nussbaum, Merve Cakir, Elizabeth M. Stein, Ryan S. Soderquist, et al. “A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Cell Rep 20, no. 4 (July 25, 2017): 999–1015. https://doi.org/10.1016/j.celrep.2017.07.006.

Ali, Moiez, Erin Kaltenbrun, Grace R. Anderson, Sarah Jo Stephens, Sabrina Arena, Alberto Bardelli, Christopher M. Counter, and Kris C. Wood. “Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.Nat Commun 8 (June 8, 2017): 15617. https://doi.org/10.1038/ncomms15617.

Pershing, Nicole L. K., Chi-Fu Jeffrey Yang, MengMeng Xu, and Christopher M. Counter. “Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.Oncotarget 7, no. 27 (July 5, 2016): 42385–92. https://doi.org/10.18632/oncotarget.9874.

Weyandt, Jamie D., John M. Carney, Elizabeth N. Pavlisko, MengMeng Xu, and Christopher M. Counter. “Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.Plos One 11, no. 12 (2016): e0167205. https://doi.org/10.1371/journal.pone.0167205.

Counter, Chris. “Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.Redox Biol 5 (August 2015): 417. https://doi.org/10.1016/j.redox.2015.09.023.

Kashatus, Jennifer A., Aldo Nascimento, Lindsey J. Myers, Annie Sher, Frances L. Byrne, Kyle L. Hoehn, Christopher M. Counter, and David F. Kashatus. “Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.Mol Cell 57, no. 3 (February 5, 2015): 537–51. https://doi.org/10.1016/j.molcel.2015.01.002.

Issaq, Sameer H., Kian-Huat Lim, and Christopher M. Counter. “Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.Mol Cancer Res 8, no. 2 (February 2010): 223–31. https://doi.org/10.1158/1541-7786.MCR-09-0189.

Lim, Kian-Huat, Donita C. Brady, David F. Kashatus, Brooke B. Ancrile, Channing J. Der, Adrienne D. Cox, and Christopher M. Counter. “Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.Mol Cell Biol 30, no. 2 (January 2010): 508–23. https://doi.org/10.1128/MCB.00916-08.

Petersen, Thomas H., Thomas Hitchcock, Akihito Muto, Elizabeth A. Calle, Liping Zhao, Zhaodi Gong, Liqiong Gui, et al. “Utility of telomerase-pot1 fusion protein in vascular tissue engineering.Cell Transplant 19, no. 1 (2010): 79–87. https://doi.org/10.3727/096368909X478650.

O’Hayer, Kevin M., Donita C. Brady, and Christopher M. Counter. “ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis.Carcinogenesis 30, no. 11 (November 2009): 1841–47. https://doi.org/10.1093/carcin/bgp198.

Kendellen, Megan F., Katharine S. Barrientos, and Christopher M. Counter. “POT1 association with TRF2 regulates telomere length.Mol Cell Biol 29, no. 20 (October 2009): 5611–19. https://doi.org/10.1128/MCB.00286-09.

Naini, Sarasija, Katherine T. Etheridge, Stacey J. Adam, Stephen J. Qualman, Rex C. Bentley, Christopher M. Counter, and Corinne M. Linardic. “Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.Cancer Res 68, no. 23 (December 1, 2008): 9583–88. https://doi.org/10.1158/0008-5472.CAN-07-6178.

Lee, Yi-Shan, Kian-Huat Lim, Xing Guo, Yoshiharu Kawaguchi, Yasheng Gao, Tomasa Barrientos, Peter Ordentlich, Xiao-Fan Wang, Christopher M. Counter, and Tso-Pang Yao. “The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.Cancer Res 68, no. 18 (September 15, 2008): 7561–69. https://doi.org/10.1158/0008-5472.CAN-08-0188.

Lee, Yi-Shan, Kian-Huat Lim, Xing Guo, Yoshiharu Kawaguchi, Yasheng Gao, Tomasa Barrientos, Peter Ordentlich, Xiao-Fan Wang, Christopher M. Counter, and Tso-Pang Yao. “The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.” Cancer Research 68, no. 18 (September 15, 2008): 7561–69. https://doi.org/10.1158/0008-5472.CAN-08-0188.

Barrientos, Katharine S., Megan F. Kendellen, Brian D. Freibaum, Blaine N. Armbruster, Katherine T. Etheridge, and Christopher M. Counter. “Distinct functions of POT1 at telomeres.Mol Cell Biol 28, no. 17 (September 2008): 5251–64. https://doi.org/10.1128/MCB.00048-08.

Tomlinson, Rebecca L., Eladio B. Abreu, Tania Ziegler, Hinh Ly, Christopher M. Counter, Rebecca M. Terns, and Michael P. Terns. “Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells.Mol Biol Cell 19, no. 9 (September 2008): 3793–3800. https://doi.org/10.1091/mbc.e08-02-0184.

Freibaum, Brian D., and Christopher M. Counter. “The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2.J Biol Chem 283, no. 35 (August 29, 2008): 23671–76. https://doi.org/10.1074/jbc.M800388200.

Lim, Kian-Huat, Brooke B. Ancrile, David F. Kashatus, and Christopher M. Counter. “Tumour maintenance is mediated by eNOS.Nature 452, no. 7187 (April 3, 2008): 646–49. https://doi.org/10.1038/nature06778.

Etheridge, Katherine T., Sarah A. Compton, Katharine S. Barrientos, Sezgin Ozgur, Jack D. Griffith, and Christopher M. Counter. “Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation.J Biol Chem 283, no. 11 (March 14, 2008): 6935–41. https://doi.org/10.1074/jbc.M708711200.

Ancrile, Brooke B., Kevin M. O’Hayer, and Christopher M. Counter. “Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.Mol Interv 8, no. 1 (February 2008): 22–27. https://doi.org/10.1124/mi.8.1.6.

Adam, Stacey J., and Christopher M. Counter. “A method to generate genetically defined tumors in pigs.Methods Enzymol 439 (2008): 39–51. https://doi.org/10.1016/S0076-6879(07)00404-1.

Linardic, Corinne M., and Christopher M. Counter. “Genetic modeling of Ras-induced human rhabdomyosarcoma.Methods Enzymol 438 (2008): 419–27. https://doi.org/10.1016/S0076-6879(07)38028-2.

Schook, L. B., K. Kuzmuk, S. Adam, L. Rund, K. Chen, M. Rogatcheva, M. Mazur, C. Pollock, and C. Counter. “DNA-based animal models of human disease: from genotype to phenotype.Dev Biol (Basel) 132 (2008): 15–25. https://doi.org/10.1159/000317140.

Rogatcheva, Margarita B., Krista L. Fritz, Laurie A. Rund, Callie B. Pollock, Jonathan E. Beever, Christopher M. Counter, and Lawrence B. Schook. “Characterization of the porcine ATM gene: towards the generation of a novel non-murine animal model for Ataxia-Telangiectasia.Gene405, no. 1–2 (December 15, 2007): 27–35. https://doi.org/10.1016/j.gene.2007.08.014.

Banik, S. S. R., and C. M. Counter. “From bread to bedside: What budding yeast has taught us about the immortalization of cancer cells,” December 1, 2007, 123–39. https://doi.org/10.1007/978-1-4020-5963-6_5.

Ancrile, Brooke, Kian-Huat Lim, and Christopher M. Counter. “Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.Genes Dev 21, no. 14 (July 15, 2007): 1714–19. https://doi.org/10.1101/gad.1549407.

Linardic, Corinne M., Sarasija Naini, James E. Herndon, Chimen Kesserwan, Stephen J. Qualman, and Christopher M. Counter. “The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.Cancer Res 67, no. 14 (July 15, 2007): 6691–99. https://doi.org/10.1158/0008-5472.CAN-06-3210.

Adam, S. J., L. A. Rund, K. N. Kuzmuk, J. F. Zachary, L. B. Schook, and C. M. Counter. “Genetic induction of tumorigenesis in swine.Oncogene 26, no. 7 (February 15, 2007): 1038–45. https://doi.org/10.1038/sj.onc.1209892.

Lim, Kian-Huat, Kevin O’Hayer, Stacey J. Adam, S Disean Kendall, Paul M. Campbell, Channing J. Der, and Christopher M. Counter. “Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.Curr Biol 16, no. 24 (December 19, 2006): 2385–94. https://doi.org/10.1016/j.cub.2006.10.023.

Freibaum, Brian D., and Christopher M. Counter. “hSnm1B is a novel telomere-associated protein.J Biol Chem 281, no. 22 (June 2, 2006): 15033–36. https://doi.org/10.1074/jbc.C600038200.

Kendall, S DiSean, Stacey J. Adam, and Christopher M. Counter. “Genetically engineered human cancer models utilizing mammalian transgene expression.Cell Cycle 5, no. 10 (May 2006): 1074–79. https://doi.org/10.4161/cc.5.10.2734.

Baines, Antonio T., Kian-Huat Lim, Janiel M. Shields, John M. Lambert, Christopher M. Counter, Channing J. Der, and Adrienne D. Cox. “Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.Methods Enzymol 407 (2006): 556–74. https://doi.org/10.1016/S0076-6879(05)07045-X.

O’Hayer, Kevin M., and Christopher M. Counter. “A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro.Methods Enzymol 407 (2006): 637–47. https://doi.org/10.1016/S0076-6879(05)07050-3.

Kendall, S DiSean, Corinne M. Linardic, Stacey J. Adam, and Christopher M. Counter. “A network of genetic events sufficient to convert normal human cells to a tumorigenic state.Cancer Res 65, no. 21 (November 1, 2005): 9824–28. https://doi.org/10.1158/0008-5472.CAN-05-1543.

Lim, Kian-Huat, and Christopher M. Counter. “Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.Cancer Cell 8, no. 5 (November 2005): 381–92. https://doi.org/10.1016/j.ccr.2005.10.014.

Kassem, Moustapha, Jorge Burns, and Basem Abd-Allah. “Blood vessels engineered from human cells.Lancet 366, no. 9489 (September 10, 2005): 891–92. https://doi.org/10.1016/S0140-6736(05)67311-4.

Poh, Melissa, Matthew Boyer, Amy Solan, Shannon L. M. Dahl, Dawn Pedrotty, Soma S. R. Banik, J Andrew McKee, Rebecca Y. Klinger, Christopher M. Counter, and Laura E. Niklason. “Blood vessels engineered from human cells.Lancet 365, no. 9477 (June 18, 2005): 2122–24. https://doi.org/10.1016/S0140-6736(05)66735-9.

Lim, Kian-Huat, Antonio T. Baines, James J. Fiordalisi, Michail Shipitsin, Larry A. Feig, Adrienne D. Cox, Channing J. Der, and Christopher M. Counter. “Activation of RalA is critical for Ras-induced tumorigenesis of human cells.Cancer Cell 7, no. 6 (June 2005): 533–45. https://doi.org/10.1016/j.ccr.2005.04.030.

Linardic, Corinne M., Diane L. Downie, Stephen Qualman, Rex C. Bentley, and Christopher M. Counter. “Genetic modeling of human rhabdomyosarcoma.Cancer Res 65, no. 11 (June 1, 2005): 4490–95. https://doi.org/10.1158/0008-5472.CAN-04-3194.

Veldman, Timothy, Katherine T. Etheridge, and Christopher M. Counter. “Loss of hPot1 function leads to telomere instability and a cut-like phenotype.Curr Biol 14, no. 24 (December 29, 2004): 2264–70. https://doi.org/10.1016/j.cub.2004.12.031.

Banik, Soma S. R., and Christopher M. Counter. “Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR.J Biol Chem 279, no. 50 (December 10, 2004): 51745–48. https://doi.org/10.1074/jbc.M408131200.

Swanson, Kelly S., Meredith J. Mazur, Kapil Vashisht, Laurie A. Rund, Jonathan E. Beever, Christopher M. Counter, and Lawrence B. Schook. “Genomics and clinical medicine: rationale for creating and effectively evaluating animal models.Exp Biol Med (Maywood) 229, no. 9 (October 2004): 866–75. https://doi.org/10.1177/153537020422900902.

Lim, Kian-Huat, and Christopher M. Counter. “Leveling the playing field.Mol Cell 15, no. 4 (August 27, 2004): 491–92. https://doi.org/10.1016/j.molcel.2004.08.014.

Armbruster, Blaine N., Corinne M. Linardic, Tim Veldman, Niharika P. Bansal, Diane L. Downie, and Christopher M. Counter. “Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1.Mol Cell Biol 24, no. 8 (April 2004): 3552–61. https://doi.org/10.1128/mcb.24.8.3552-3561.2004.

Yeh, Elizabeth, Melissa Cunningham, Hugh Arnold, Dawn Chasse, Teresa Monteith, Giovanni Ivaldi, William C. Hahn, et al. “A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.Nat Cell Biol 6, no. 4 (April 2004): 308–18. https://doi.org/10.1038/ncb1110.

Rogatcheva, Margarita M., Laurie A. Rund, Kelly S. Swanson, Brandy M. Marron, Jonathan E. Beever, Christopher M. Counter, and Lawrence B. Schook. “Creating porcine biomedical models through recombineering.Comp Funct Genomics 5, no. 3 (2004): 262–67. https://doi.org/10.1002/cfg.404.

Guo, Chuanhai, Blaine N. Armbruster, David T. Price, and Christopher M. Counter. “In vivo regulation of hTERT expression and telomerase activity by androgen.J Urol 170, no. 2 Pt 1 (August 2003): 615–18. https://doi.org/10.1097/01.ju.0000074653.22766.c8.

McKee, J Andrew, Soma S. R. Banik, Matthew J. Boyer, Nesrin M. Hamad, Jeffrey H. Lawson, Laura E. Niklason, and Christopher M. Counter. “Human arteries engineered in vitro.Embo Rep 4, no. 6 (June 2003): 633–38. https://doi.org/10.1038/sj.embor.embor847.

Rich, Jeremy N., Qing Shi, Mark Hjelmeland, Thomas J. Cummings, Chien-Tsun Kuan, Darell D. Bigner, Christopher M. Counter, and Xiao-Fan Wang. “Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.J Biol Chem 278, no. 18 (May 2, 2003): 15951–57. https://doi.org/10.1074/jbc.M211498200.

Armbruster, Blaine N., Katherine T. Etheridge, Dominique Broccoli, and Christopher M. Counter. “Putative telomere-recruiting domain in the catalytic subunit of human telomerase.Mol Cell Biol 23, no. 9 (May 2003): 3237–46. https://doi.org/10.1128/mcb.23.9.3237-3246.2003.

Counter, Christopher M., William Press, and Carolyn C. Compton. “Telomere shortening in cultured autografts of patients with burns.Lancet 361, no. 9366 (April 19, 2003): 1345–46. https://doi.org/10.1016/S0140-6736(03)13042-5.

Hamad, Nesrin M., Soma S. R. Banik, and Christopher M. Counter. “Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells.Oncogene 21, no. 46 (October 10, 2002): 7121–25. https://doi.org/10.1038/sj.onc.1205860.

Banik, Soma S. R., Chuanhai Guo, Allyson C. Smith, Seth S. Margolis, D Ashley Richardson, Carlos A. Tirado, and Christopher M. Counter. “C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity.Mol Cell Biol 22, no. 17 (September 2002): 6234–46. https://doi.org/10.1128/mcb.22.17.6234-6246.2002.

Hamad, Nesrin M., Joel H. Elconin, Antoine E. Karnoub, Wenli Bai, Jeremy N. Rich, Robert T. Abraham, Channing J. Der, and Christopher M. Counter. “Distinct requirements for Ras oncogenesis in human versus mouse cells.Genes Dev 16, no. 16 (August 15, 2002): 2045–57. https://doi.org/10.1101/gad.993902.

Etheridge, Katherine T., Soma S. R. Banik, Blaine N. Armbruster, Yusheng Zhu, Rebecca M. Terns, Michael P. Terns, and Christopher M. Counter. “The nucleolar localization domain of the catalytic subunit of human telomerase.J Biol Chem 277, no. 27 (July 5, 2002): 24764–70. https://doi.org/10.1074/jbc.M201227200.

Shi, Songtao, Stan Gronthos, Shaoqiong Chen, Anand Reddi, Christopher M. Counter, Pamela G. Robey, and Cun-Yu Wang. “Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression.Nat Biotechnol 20, no. 6 (June 2002): 587–91. https://doi.org/10.1038/nbt0602-587.

Armbruster, B. N., S. S. Banik, C. Guo, A. C. Smith, and C. M. Counter. “N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo.Mol Cell Biol 21, no. 22 (November 2001): 7775–86. https://doi.org/10.1128/MCB.21.22.7775-7786.2001.

Guo, C., D. Geverd, R. Liao, N. Hamad, C. M. Counter, and D. T. Price. “Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells.J Urol 166, no. 2 (August 2001): 694–98.

Rich, J. N., C. Guo, R. E. McLendon, D. D. Bigner, X. F. Wang, and C. M. Counter. “A genetically tractable model of human glioma formation.Cancer Res 61, no. 9 (May 1, 2001): 3556–60.

Hu, P. P., X. Shen, D. Huang, Y. Liu, C. Counter, and X. F. Wang. “The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta.J Biol Chem 274, no. 50 (December 10, 1999): 35381–87. https://doi.org/10.1074/jbc.274.50.35381.

Hahn, W. C., C. M. Counter, A. S. Lundberg, R. L. Beijersbergen, M. W. Brooks, and R. A. Weinberg. “Creation of human tumour cells with defined genetic elements.Nature 400, no. 6743 (July 29, 1999): 464–68. https://doi.org/10.1038/22780.

Xie, Y., C. Counter, and E. Alani. “Characterization of the repeat-tract instability and mutator phenotypes conferred by a Tn3 insertion in RFC1, the large subunit of the yeast clamp loader.Genetics 151, no. 2 (February 1999): 499–509.

Counter, C. M., W. C. Hahn, W. Wei, S. D. Caddle, R. L. Beijersbergen, P. M. Lansdorp, J. M. Sedivy, and R. A. Weinberg. “Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization.Proc Natl Acad Sci U S A 95, no. 25 (December 8, 1998): 14723–28. https://doi.org/10.1073/pnas.95.25.14723.

Kolquist, K. A., L. W. Ellisen, C. M. Counter, M. Meyerson, L. K. Tan, R. A. Weinberg, D. A. Haber, and W. L. Gerald. “Expression of TERT in early premalignant lesions and a subset of cells in normal tissues.Nat Genet 19, no. 2 (June 1998): 182–86. https://doi.org/10.1038/554.

Counter, C. M., M. Meyerson, E. N. Eaton, L. W. Ellisen, S. D. Caddle, D. A. Haber, and R. A. Weinberg. “Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase.Oncogene 16, no. 9 (March 5, 1998): 1217–22. https://doi.org/10.1038/sj.onc.1201882.

Meyerson, M., C. M. Counter, E. N. Eaton, L. W. Ellisen, P. Steiner, S. D. Caddle, L. Ziaugra, et al. “hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.Cell 90, no. 4 (August 22, 1997): 785–95. https://doi.org/10.1016/s0092-8674(00)80538-3.

Counter, C. M., M. Meyerson, E. N. Eaton, and R. A. Weinberg. “The catalytic subunit of yeast telomerase.Proc Natl Acad Sci U S A 94, no. 17 (August 19, 1997): 9202–7. https://doi.org/10.1073/pnas.94.17.9202.

Counter, C. M. “The roles of telomeres and telomerase in cell life span.Mutat Res 366, no. 1 (October 1996): 45–63. https://doi.org/10.1016/s0165-1110(96)90006-8.

Bacchetti, S., and C. Counter. “Telomeres and telomerase in human cancer (review).Int J Oncol 7, no. 3 (September 1995): 423–32.

Counter, C. M., J. Gupta, C. B. Harley, B. Leber, and S. Bacchetti. “Telomerase activity in normal leukocytes and in hematologic malignancies.Blood 85, no. 9 (May 1, 1995): 2315–20.

Counter, C. M., F. M. Botelho, P. Wang, C. B. Harley, and S. Bacchetti. “Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes.J Virol 68, no. 5 (May 1994): 3410–14.

Counter, C. M., H. W. Hirte, S. Bacchetti, and C. B. Harley. “Telomerase activity in human ovarian carcinoma.Proc Natl Acad Sci U S A 91, no. 8 (April 12, 1994): 2900–2904. https://doi.org/10.1073/pnas.91.8.2900.

Harley, C. B., N. W. Kim, K. R. Prowse, S. L. Weinrich, K. S. Hirsch, M. D. West, S. Bacchetti, H. W. Hirte, C. M. Counter, and C. W. Greider. “Telomerase, cell immortality, and cancer.Cold Spring Harb Symp Quant Biol 59 (1994): 307–15. https://doi.org/10.1101/sqb.1994.059.01.035.


Harley, C. B., H. Vaziri, C. M. Counter, and R. C. Allsopp. “The telomere hypothesis of cellular aging.Exp Gerontol 27, no. 4 (July 1992): 375–82. https://doi.org/10.1016/0531-5565(92)90068-b.

Counter, C. M., A. A. Avilion, C. E. LeFeuvre, N. G. Stewart, C. W. Greider, C. B. Harley, and S. Bacchetti. “Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity.Embo J 11, no. 5 (May 1992): 1921–29.


Papers Reviewed By:

Li S & Counter CM (2021) Signaling levels mold the RAS mutation tropism of urethane. Elife 10:e67172[PMC8128437] 

  • Reviewed by: Butt Z & Prior I (2021) Tumor initiation: Danger zone. Elife 10:e69192.


Adhikari H & Counter CM (2018) Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat Commun, 9:3646. [PMC6128905]

  • Reviewed by: East MP, Laitinen T & Asquith CRM (2020) PI5K1A: a potential target for cancers with KRAS or TP53 mutations. Nat Rev Drug Discov, 2020: Apr24.


Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, Counter CM & Kashatus DF (2015) Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell, 57:537-51. [PMC4393013]

  • Reviewed by: Cancer Discovery research watch (2015) MAPK-driven transformation requires DRP1-mediated mitochondrial division. Cancer Discov, 5:OF10


Pershing NLK, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM & Counter CM (2015) Rare codons capacitate Kras-driven de novo tumorigenesis. J Clin Invest, 125:222-33. [PMC4382256]

  • Reviewed by: JCI Editors (2015) Cracking the codon bias of KRAS in tumorigenesis. JCI Impact, January 2015:8.


Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ & Counter CM (2014) Copper is required for oncogenic BRAF signaling and tumorigenesis. Nature, 509:492-6. [PMC4138975]

  • Reviewed by: Lokody I (2014) Inhibiting oncogenic BRAF signaling by copper depletion. Nat Rev Cancer, 14:384-5. Everts S (2014) Copper’s role in cancer. Chem Eng News, 92:23-4. Nature Editorial (2014) Copper rewired. Nature, 508:150.  Jarrett SG & D’Orazio JA (2014) Ctr1-ing BRAF signaling with copper. Pigment Cell Melanoma Res, 27:689-91Tsai KY (2014) Cupric needs: Copper is necessary for oncogenic BRAF signaling. NEJM Journal Watch, May 22, 2014.


Lampson BL, Pershing NLK*, Prinz JA*, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM & Counter CM(2013) Rare codons regulate KRas function. Curr Biol, 23:70-9. [PMC3567844]

  • Reviewed by: Bodeman BO & White MA (2013) Ras GTPases: Codon bias holds KRas down but not out. Curr Biol 23:R17-9.


Lampson BL*, Kendall SD*, Ancrile BB*, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM & Counter CM (2012) Targeting eNOS in pancreatic cancer. Cancer Res, 72:4472-82. [PMC3749841]

  • Reviewed by: Cancer Research editors (2012) Breaking Advances: Highlights from recent cancer literature. Targeting eNOS in pancreatic cancer: A long road ahead. Cancer Res, 72:8473-4.


Turski ML*, Brady DC*, Kim HJ, Kim B-E, Nose Y, Counter CM, Winge DR & Thiele DJ (2012) A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol, 32:1284-95. [PMC3302449]

  • Reviewed by: VanHook AM (2012) Editor’s choice: Copper as a kinase cofactor. Sci Signal, 5:ec84.


Kashatus DF, Lim K-H, Brady DC, Pershing NLK, Cox AD & Counter CM (2011) RalA and RalBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol, 13:1108-15. [PMC3167028] (191 citations)

  • Reviewed by: Yamano K & Youle RJ (2011) Coupling mitochondrial and cell division. Nat Cell Biol, 13:1026-7.  Hurtley SM (2011) Editor’s choice, cell biology: Divide to survive. Science, 333:1681.  Maia AR & Maiato H (2011) Aurora mitochondrialis drive fission during mitosis. Dev Cell, 21:387-8.  Gough NR (2011) Editor’s choice, cell cycle: Ensuring adequate energy supply. Sci Signal, 4:ec273.


Lim K-H*, Ancrile BB*, Kashatus DF* & Counter CM (2008) eNOS mediates tumour maintenance. Nature, 452: 646-50. [PMC2688829]

  • Reviewed by: Novak K (2008) Follow you eNOS. Nat Rev Cancer, 8:322-3.  Larsen CJ (2008) Nitrosylation of Ras proteins is required to initiate and sustain tumoral growth. Bulletin du Cancer, 95:485.


Ancrile BB, Lim K-H & Counter CM (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev, 21: 1714-9. [PMC1920165]

  • Reviewed by: Diaz-Flores E & Shannon K (2007) Targeting oncogenic Ras. Genes Dev, 21:1989-92.


Linardic CM, Downie DL, Qualman S, Bentley RC & Counter CM (2005) Genetic modeling of human rhabdomyosarcoma. Cancer Res, 65:4490-5. [PMID: 15930263]

  • Reviewed by: Cancer research highlights June 1, 2005: RMS model opens avenues for understanding malignancy mechanisms.


Poh M, Boyer M, Solan A, Mitchell S, Pedrotty D, Banik SSR, McKee JA, Counter CM & Niklason LE (2005) Blood vessels engineered from human cells. Lancet, 365:2122-4. [PMID: 15964449]

  • Reviewed by: Brey EM & Greisler HP (2005) Telomerase expression in somatic cells. Lancet. 365:2068-9.


Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR & Sears R (2004) A signaling pathway controlling Myc degredation that impacts oncogenic transformation of human cells. Nat Cell Biol, 6:308-18. [PMID: 15048125]

  • Reviewed by: Dominguez-Sola D & Dalla-Favera R (2004) PINing down the c-Myc oncoprotein. Nat Cell Biol, 6:288-9.


McKee JA, Banik SSR, Boyer MJ, Hamad N, Lawson JH, Niklason LE* & Counter CM* (2003) Human arteries engineered in vitro. EMBO Rep, 4:633-8. [PMC1319197]

  • Reviewed by: Journal editors (2003) Immortalized cells help researchers grow human arteries. ASBMB Today 2:6-7.


Counter CM, Press W & Compton CC (2003) Telomere shortening in cultured autografts of patients with burns. Lancet, 361:1345-6. [PMID: 12711471]

  • Reviewed by: Navsaria HA & Rugg EL (2003) Telomere shortening: Significant for keratinocyte grafting? Lancet, 361:1316-7.  Journal editors (2003) Growing human skin in laboratory can prematurely age cells. ASBMB Today 2:8-9.


Hamad NM, Elconin JE, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ & Counter CM (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev, 16:2045-57. [PMC186434]

  • Reviewed by: Kiberstis PA (2002) Editor’s choice: Steinbeck redux Science, 297:1447.  Boettner B & Van Aelst L (2002) The RASputin effect. Genes Dev, 16:2033-8.  Habeck M (2002) Of mice and men, and cancer research. Drug Disc Today, 7:981-2.  Habeck M (2002) Cancers with Ras may have an Archilles Heel. Lancet Oncol, 3:586.  Highlights in brief: Oncogenes (2002) Nat Rev Cancer 2:721.


Hahn WC*, Counter CM*, Lundberg AS, Beijersbergen RL, Brooks MW & Weinberg RA (1999) Creation of human tumor cells with defined genetic elements. Nature, 400:464-8. [PMID: 10440377]

  • Reviewed by: Weitzman JB & Yaniv M (1999) Rebuilding the road to cancer. Nature, 400:401-402.  Reed C (1999) A model tumor. Sci Am October 1999.


Counter CM*, Hahn WC*, Wei W, Caddle SD, Beijersbergen RL, Lansdorp P, Sedivy JM & Weinberg RA (1998) Dissociation between telomerase activity, telomere maintenance and cellular immortalization. Proc Natl Acad Sci USA, 95:14723-8. [PMC24516]

  • Reviewed by: Lustig AJ (1998) Crisis intervention: a role for telomerase. Proc Natl Acad Sci USA, 96:3339-3341.


Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA & Gerald WL (1998) Expression of hTERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet, 19:182-6. [PMID: 9620778]

  • Reviewed by: (1998) Be fruitful and multiple. Nat Genet, 19:103-4.


Meyerson M*, Counter CM*, Ng Eaton E, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA & Weinberg RA (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-tegulated in tumor cells and during immortalization. Cell, 90:785-95. [PMID: 9288757]

  • Reviewed by:  Smaglik P (1999) Hot papers in telomerase. The Scientist, 13:14.  Kolberg R (1997) Nailing the gene for telomerase’s controller- twice. J NIH Res, 9:23-25.


Counter CM, Gupta J, Harley CB, Leber B & Bacchetti S (1995) Telomerase activity in normal leukocytes and in hematological malignancies. Blood, 85:2315-20. [PMID: 7727765]

  • Reviewed by: Young Kreeger K (1995) Hot papers- Telomere biology. The Scientist, 11:15.


Counter CM, Hirte HW, Bacchetti S & Harley CB (1994) Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA, 91:2900-4. [PMC43481]

  • Reviewed by: de Lange T (1994) Activation of telomerase in a human tumor. Proc Natl Acad Sci USA, 91:2882-5.  Borman S (1994) Study suggests telomerase inhibitors could be effective anticancer drugs. Chem Eng News, 72:42-4.  Rennie J (1994) Immortal’s enzyme. Sci Am, July:14-5.  Cancer cell’s fountain of youth. (1994) Biomed, May:319.  Hopkin K (1994) MTS1, telomerase may be new targets for cancer therapy. J NIH Res, 6:3838-42.